Switch theme
Sign up to access all valuation multiples
Sundrug Co Ltd is a Japanese based company engaged in the operations and management of drugstores. Its activities are divided into business divisions including Drugstore business, Dispensing pharmacy business, and Discount store business. The company also offers necessities such as foods, cosmetics, household appliances, clothing items, car goods, sports and leisure goods, alcoholic beverages, kerosene through its discount store Direx.
1965
13.2K+
LTM Revenue $5.6B
LTM EBITDA $433M
$3.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sundrug has a last 12-month revenue (LTM) of $5.6B and a last 12-month EBITDA of $433M.
In the most recent fiscal year, Sundrug achieved revenue of $5.2B and an EBITDA of $387M.
Sundrug expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sundrug valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $5.6B | XXX | $5.2B | XXX | XXX | XXX |
| Gross Profit | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| Gross Margin | 24% | XXX | 25% | XXX | XXX | XXX |
| EBITDA | $433M | XXX | $387M | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | 8% | XXX | XXX | XXX |
| EBIT | $310M | XXX | $281M | XXX | XXX | XXX |
| EBIT Margin | 6% | XXX | 5% | XXX | XXX | XXX |
| Net Profit | $214M | XXX | $200M | XXX | XXX | XXX |
| Net Margin | 4% | XXX | 4% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Sundrug's stock price is JPY 4491 (or $31).
Sundrug has current market cap of JPY 525B (or $3.6B), and EV of JPY 499B (or $3.4B).
See Sundrug trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.4B | $3.6B | XXX | XXX | XXX | XXX | $1.83 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Sundrug has market cap of $3.6B and EV of $3.4B.
Sundrug's trades at 0.7x EV/Revenue multiple, and 9.1x EV/EBITDA.
Equity research analysts estimate Sundrug's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sundrug has a P/E ratio of 16.9x.
See valuation multiples for Sundrug and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.6B | XXX | $3.6B | XXX | XXX | XXX |
| EV (current) | $3.4B | XXX | $3.4B | XXX | XXX | XXX |
| EV/Revenue | 0.6x | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBITDA | 7.9x | XXX | 9.1x | XXX | XXX | XXX |
| EV/EBIT | 11.0x | XXX | 12.4x | XXX | XXX | XXX |
| EV/Gross Profit | 2.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 16.9x | XXX | 18.6x | XXX | XXX | XXX |
| EV/FCF | 74.8x | XXX | 99.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSundrug's last 12 month revenue growth is 7%
Sundrug's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Sundrug's rule of 40 is 15% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sundrug's rule of X is 26% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sundrug and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | 15% | XXX | XXX | XXX |
| Rule of 40 | 15% | XXX | 15% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 26% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 20% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| SC Ropharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sundrug acquired XXX companies to date.
Last acquisition by Sundrug was XXXXXXXX, XXXXX XXXXX XXXXXX . Sundrug acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sundrug founded? | Sundrug was founded in 1965. |
| Where is Sundrug headquartered? | Sundrug is headquartered in Japan. |
| How many employees does Sundrug have? | As of today, Sundrug has 13.2K+ employees. |
| Who is the CEO of Sundrug? | Sundrug's CEO is Mr. Hiroshi Sadakata. |
| Is Sundrug publicy listed? | Yes, Sundrug is a public company listed on TKS. |
| What is the stock symbol of Sundrug? | Sundrug trades under 9989 ticker. |
| When did Sundrug go public? | Sundrug went public in 1997. |
| Who are competitors of Sundrug? | Similar companies to Sundrug include e.g. MedPlus India, SC Ropharma, Pague Menos, Droga Raia. |
| What is the current market cap of Sundrug? | Sundrug's current market cap is $3.6B |
| What is the current revenue of Sundrug? | Sundrug's last 12 months revenue is $5.6B. |
| What is the current revenue growth of Sundrug? | Sundrug revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Sundrug? | Current revenue multiple of Sundrug is 0.6x. |
| Is Sundrug profitable? | Yes, Sundrug is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sundrug? | Sundrug's last 12 months EBITDA is $433M. |
| What is Sundrug's EBITDA margin? | Sundrug's last 12 months EBITDA margin is 8%. |
| What is the current EV/EBITDA multiple of Sundrug? | Current EBITDA multiple of Sundrug is 7.9x. |
| What is the current FCF of Sundrug? | Sundrug's last 12 months FCF is $45.7M. |
| What is Sundrug's FCF margin? | Sundrug's last 12 months FCF margin is 1%. |
| What is the current EV/FCF multiple of Sundrug? | Current FCF multiple of Sundrug is 74.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
